Merck Research Laboratories

Latest stories

21d
News-Medical-Net
Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapyMerck and The University of Texas MD Anderson Cancer Center announced a strateg
Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy
News-Medical-Net / Posted 21 days ago
Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation... Read more
22d
NJ Biz
Merck, MD Anderson Cancer Center announce research collaborationKenilworth-based Merck and The University of Texas MD Anderson Cancer Center an
Merck, MD Anderson Cancer Center announce research collaboration
NJ Biz / Posted 22 days ago
Kenilworth-based Merck and The University of Texas MD Anderson Cancer Center announced Thursday that the pair has entered into a clinical research partnership to evaluate Merck’s immuno-oncology therapy options. Under the agreement, collaborative... Read more
22d
Philly.com
Merck, University of Texas MD Anderson Cancer Center add to cancer partnershipMerck hopes to make big profits from extending the Keytruda concept and franchi
Merck, University of Texas MD Anderson Cancer Center add to cancer partnership
Philly.com / Posted 22 days ago
Merck hopes to make big profits from extending the Keytruda concept and franchise to as many cancers as possible. Parallel trials mean testing different ideas at the same time and bringing any and all the successful ones to market as soon as... Read more
m
Business Wire
In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is ContinuingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canad
In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
Business Wire / Posted 1 months ago
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring... Read more
212 related stories

People in this news